Michael Pollan Answers Psychedelics Questions from Twitter

Journalist Michael Pollan, author of How to Change Your Mind, answers psychedelics questions pulled from Twitter in a fast, roughly fifteen-minute segment for WIRED's Tech Support series. The rapid-fire format keeps answers short, but together they cover how LSD works in the brain, what ego death is, whether microdosing does anything, and why psychedelic research remains legally stalled despite promising results. Pollan is candid throughout about where the science ends and speculation begins.

How LSD works in the brain

LSD is shaped enough like serotonin, a mood-related neurotransmitter, that it fits the brain's serotonin receptors even more tightly than serotonin itself, Pollan explains. It acts as an agonist, activating the receptor rather than blocking it, which he says is one reason its effects last so long. Beyond that binding, he is direct about the limits of current knowledge: researchers can describe the receptor mechanism but not the full cascade to altered perception. "You would be amazed," he says, "how little we understand about how the brain works."

Why DMT looks different from LSD and mushrooms

Asked why DMT tends toward sharp geometric visuals while LSD and mushrooms feel more organic, Pollan points less to pharmacology than to set and setting, psychologist Timothy Leary's term for expectation and physical context. On ayahuasca, a DMT-containing brew, people in the Amazon often report jungle animals; DMT users elsewhere often describe small humanoid figures some call "machine elves," a motif the writer Terence McKenna popularized. Pollan suspects the imagery reflects expectation more than chemistry.

Safety: bad trips and why guided support matters

Pollan says he knows of no documented cases of a psychedelic permanently altering the brain or erasing memory, though psychotic breaks and triggered schizophrenia are real, if uncommon, risks, part of why trials exclude people at elevated risk. For difficult moments, he cites guidance from research trials, sometimes called "flight instructions": if things start to feel like dying, melting, or dissolving, relax and let it move through rather than fighting it. Confronting old trauma is often part of the process, which is why having someone present, and someone to help process it afterward, matters as much as the session itself. Psylopedia's integration guide covers that follow-up work.

Ego death: what it is and why people seek it

Ego death, in Pollan's description, is what some people experience on a high dose: a felt collapse of the ordinary sense of self. He recounts his own experience from How to Change Your Mind, seeing himself dissolve into a cloud of Post-it notes that fell and spread into a sheet of blue paint, and recognizing it as himself. The appeal, he says, is what can follow: a sense of merging with nature, the cosmos, or other people once the usual boundaries of self loosen. It does not happen on every high-dose experience, but when it does, he calls it one of the more striking experiences a person can have. Psylopedia's explainer on ego death goes deeper into what research suggests.

Microdosing: popular, but the evidence is thin

Microdosing means taking a fraction, roughly a tenth by Pollan's description, of a full dose, low enough that effects are not meant to be consciously noticeable. Many microdosers report better mood, productivity, or creativity, but Pollan is direct that solid evidence is lacking: placebo effects are strong with any drug, and he suggests especially so with psychedelics, given the cultural expectations attached to them. Psylopedia's look at the microdosing research covers what studies so far show.

Psychedelics in therapy: anxiety, addiction, and mental illness

The research Pollan finds most striking involves giving psilocybin to people with terminal cancer. Patients he has interviewed described a single session helping them confront mortality, easing fear of death into something closer to equanimity, at a point when medicine otherwise mostly offers pain relief. Psilocybin-assisted therapy has also shown promise for addiction: Pollan cites early trials where more than half of participants who tried it quit smoking, and relays a researcher's image of the effect as shaking "the snow globe in your brain," so old patterns can shift when it settles. Other research explores psilocybin and MDMA for PTSD and depression, and early Brazilian work has looked at ibogaine for depression, though addiction-specific evidence is thinner. He also flags a caution: the disordering effect that may help rigid patterns like addiction could be riskier for people with schizophrenia, which is why trials exclude them. Psylopedia's psilocybin mushroom profile covers how this substance is being studied.

Legal status: why research stays stalled

Psychedelics remain Schedule I drugs in the US, the federal category for substances judged to have no accepted medical use, even as FDA- and DEA-approved university trials keep producing encouraging results for depression, addiction, and PTSD. The bottleneck Pollan describes is funding, not legality: with one small NIMH-grant exception (a Yale study of psilocybin for obsessive-compulsive disorder), federal money has stayed off the table, leaving research funded mostly by private philanthropy. Psylopedia's overview of psychedelic law by country covers where things stand.

A brief history: Hofmann's discovery and Cary Grant

Pollan closes with two historical notes. LSD was first synthesized by Swiss chemist Albert Hofmann while studying compounds from ergot, a fungus that grows on grain. He absorbed a small amount through his skin, noticed its effects, and later took a deliberate dose that briefly convinced him he was losing his mind before it resolved into wonder in his garden. Decades later, actor Cary Grant underwent psychedelic therapy in Los Angeles in the late 1950s and reportedly called it one of the best things he ever did.

Key takeaways

• ●LSD's long duration comes from a tight fit with serotonin receptors, though the path to altered perception is not well understood, per Pollan.
• ●Permanent harm from a single experience appears rare in Pollan's account, though triggered schizophrenia is a real risk trials screen against.
• ●DMT, LSD, and mushroom visuals may owe as much to expectation and setting as to chemistry.
• ●Ego death, a felt dissolution of self on a high dose, is not guaranteed and depends on surrendering to it rather than resisting.
• ●Microdosing is popular, but rigorous evidence has not caught up with the claims made for it.
• ●Psilocybin-assisted therapy has shown promise easing cancer-related anxiety and supporting people quitting smoking or other addictions.
• ●Psychedelics remain Schedule I in the US; the main obstacle to research is federal funding, not a lack of legal pathways for trials.
• ●Pollan closes with a reminder: psychedelics are illegal in most places and carry real mental health risks, so any interest calls for caution.